Experimental combo aims to tackle returning brain tumors
Disease control
Not yet recruiting
This early-stage trial tests whether combining vorasidenib (a targeted therapy) with lomustine (a chemotherapy) is safe for people with recurrent IDH-mutant gliomas, a type of brain cancer. About 24 adults whose tumors have returned will receive different doses to find the best o…
Phase: PHASE1 • Sponsor: Megan Mantica • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC